Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C (NCT03471143) | Clinical Trial Compass
CompletedPhase 1/2
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
United States4 participantsStarted 2019-02-22
Plain-language summary
Niemann-Pick disease, type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence. NPC results from mutation of either the Niemann-Pick C1 disease (NPC1) (\~95% of cases) or NPC2 genes. NPC is characterized by the endolysosomal storage of unesterified cholesterol and lipids in both the central nervous system and peripheral tissues such as the liver. Individuals with NPC demonstrate progressive central nervous system decline including inability to coordinate balance, gait, extremity and eye movements. Acute liver disease in the newborn/infant period is frequently observed, but subsequently resolves. However, chronic, sub-clinical liver disease persists. Intrathecal 2-Hydroxypropyl-Ī²-Cyclodextrin (HP-Ī²-CD, VTS-270), also known as adrabetadex, has proven effective in reducing the signs and prolonging life in animal models and Phase 1/2a data support efficacy in NPC1 patients. Adrabetadex (VTS-270) also has been shown to be effective in treating liver disease in the NPC1 cat.
This Phase 1/2a, open-label, multiple ascending dose trial will evaluate whether adrabetadex (VTS-270) administered intravenously is effective in treating acute liver disease in NPC1 infants.
Who can participate
Age range6 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age 0 to 6 months of age at time of enrollment, both genders, and any race/ethnicity.
ā. Diagnosis of NPC (either NPC1 or NPC2) based upon meeting any of the two following conditions:
ā. Subjects with evidence of NPC-related liver disease as defined by direct bilirubin (DB) \>2mg/dL or DB/total bilirubin ratio \>0.2.
ā. Ability to travel to a research site.
ā. Willing to participate in all aspects of trial design including serial blood collections.
ā. Parent / guardian must provide written informed consent to participate in the study. Because of the age range intended for inclusion, assent will not possible.
Exclusion criteria
ā. Age \> 6 months at time of enrollment in the trial.
ā. A medical condition (such as clinically significant bleeding diathesis or evidence of immune suppression) that in the opinion of the investigator precludes placement of an intravenous catheter
What they're measuring
1
Efficacy of Adrabetadex (VTS-270) to Reduce Plasma Levels of a Conjugated Bile Acid, Known as 5Ī±-cholanic Acid-3Ī², 5Ī±, 6Ī²-triol N-(Carboxymethyl)-Amide
. An absolute neutrophil count (ANC) of less than 1,500 per microliter.
ā. A platelet count less than 75,000 per microliter.
ā. History of severe neonatal encephalopathy, per modified Sarnat including level of consciousness as stupor/coma, absent spontaneous activity, decerebrate posture, flaccid tone, absent suck, absent moro, diverted/nonreactive pupils, lack of heart rate variability, apnea.
ā. Subjects, who in the opinion of the investigators, are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation. Examples of inability to comply include unwillingness to relocate or travel to a study site, suspected noncompliance with study procedures, behavior that jeopardizes the safety or security of the data or study staff, and other causes of inability to comply.
ā. Concurrent participation in another investigational drug trial.
ā. History of renal disease or evidence of acute kidney injury defined as serum creatinine greater than 1.5 mg/dL or an increase of at least 0.2-0.3 mg/dL per day.